regardless of encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from PBMs. The organizations are typically building limitations to access, such as steep expense restrictions and PA that restrict user access. Industry indicate that these reimbu